HIGHLIGHTS
- who: Glioblastoma MGMT Promoter and collaborators from the Département de Biologie, Centre Eugène Marquis, CS, France have published the research: Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients, in the Journal: (JOURNAL)
- what: The authors extended the PSQ analysis to CpGs (CpGs identified as critical for transcriptional control of the gene. The authors analyzed 16 CpGs by PSQ with a customdesigned test and sought to determine which individual CpG, or combination of CpGs is best at predicting therapeutic response in a cohort of newly diagnosed GBM patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.